Letter: Association of serum growth differentiation factor 15 and liver-related outcomes in patients with MASLD-Authors' reply
- PMID: 39075770
- DOI: 10.1111/apt.18186
Letter: Association of serum growth differentiation factor 15 and liver-related outcomes in patients with MASLD-Authors' reply
References
REFERENCES
-
- Wang J, Fan T, Zhang S, Wu C, Huang R. Letter: association of serum growth differentiation factor 15 and liver‐related outcomes in patients with MASLD. Aliment Pharmacol Ther. 2024;60:825–826.
-
- Kumazaki S, Hikita H, Tahata Y, Sung JH, Fukumoto K, Myojin Y, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Aliment Pharmacol Ther. 2024;60:327–339. https://doi.org/10.1111/apt.18063
-
- Huang DQ, El‐Serag HB, Loomba R. Global epidemiology of NAFLD‐related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238. https://doi.org/10.1038/s41575‐020‐00381‐6
-
- Liu H, Huang Y, Lyu Y, Dai W, Tong Y, Li Y. GDF15 as a biomarker of ageing. Exp Gerontol. 2021;146:111228. https://doi.org/10.1016/j.exger.2021.111228
-
- Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444–448. https://doi.org/10.1038/s41586‐019‐1911‐y
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources